Keensight Capital Acquires Majority Stake In Bedfont® Scientific Ltd., A Global Leader In Non-invasive Breath Analysis Devices

Keensight Capital (“Keensight”), 1 of nan starring backstage equity managers dedicated to pan-European Growth Buyou investments, coming announced it has acquired a mostly liking in Bedfont® Scientific Ltd. (“Bedfont”), which designs and manufactures non-invasive activity study aesculapian devices. As portion of nan transaction, nan Company’s existing shareholders will reinvest alongside Keensight.

Founded successful 1976 and headquartered successful Maidstone, UK, Bedfont is simply a world leader successful non-invasive activity study devices, supporting not only medical diagnosis but besides nan monitoring and guidance of respiratory and metabolic conditions. The Company designs and manufactures high-precision activity and state study instruments, pinch a peculiar attraction connected nan NObreath® instrumentality for FeNO testing, a cardinal biomarker for asthma test and guidance which is progressively being adopted crossed healthcare systems. Bedfont’s portfolio besides includes solutions for smoking cessation and hydrogen and methane activity testing for gastrointestinal disorders.

Bedfont’s products are wide utilized crossed superior and secondary healthcare settings, distributed done a web of complete 100 partners successful much than 70 countries worldwide. By leveraging innovative technology, nan Company makes cutting-edge activity study much accessible globally and contributes to raising standards of attraction successful nan healthcare system.

With a beardown way grounds successful some MedTech and nan respiratory field, Keensight brings nan expertise and web to support Bedfont’s adjacent shape of growth, strengthening its position arsenic a world leader successful activity study field. By leveraging its world footprint and nan resources of nan Performance team, Keensight will activity hand-in-hand pinch guidance to accelerate maturation and world description , some organically and done acquisitions, while further scaling innovation.

We spot important opportunity to grow nan usage of activity study successful aesculapian test and monitoring. It is captious that this exertion is reliable and accessible. Our imagination is simply a world wherever everyone has entree to instant, non-invasive, elemental activity testing. With nan support of Keensight, we will beryllium capable to summation diligent outreach and amended diligent entree worldwide.”

Jason Smith, CEO, Bedfont Scientific

Amit Karna, Partner astatine Keensight Capital, added: "Bedfont is simply a highly innovative institution whose pioneering activity successful activity biomarkers, peculiarly FeNO, is helping to beforehand world standards successful respiratory diagnostics. We are thrilled to partner pinch nan family down Bedfont, together pinch itsvisionary CEO Jason Smith, to support nan institution arsenic it enters its adjacent shape of world maturation and development."